RxDoctor Payments DataLook up a doctor →

Natalya Belotserkovskaya, MD

Neurology · Birmingham, ALNPI 1164833323

Payments from drug & device makers

$41,755in general payments, 2019–2025

Across 854 payments — averaging $48.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$16K
  • Amgen$4K
  • Pfizer$3K
  • Genentech USA, Inc.$2K
  • AbbVie$2K
  • Novartis$1K
  • plus $12K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen47$16,443
Amgen(2 entities)59$4,289
Pfizer61$2,610
Genentech USA, Inc.19$2,439
AbbVie154$2,312
Novartis66$1,425
UCB, Inc.38$1,150
Genentech, Inc.4$1,123
AstraZeneca(2 entities)39$1,051
Lilly USA, LLC46$924
Argenx US, Inc.27$789
Lundbeck LLC21$522
Sanofi10$521
Neurocrine Biosciences, Inc.24$506
Eisai Inc.16$481
Bristol Myers Squibb18$479
Acorda Therapeutics, Inc19$412
EMD Serono, Inc.17$406
Acadia Pharmaceuticals Inc21$358
Takeda Pharmaceuticals U.S.A., Inc.13$308
TG Therapeutics, Inc.13$300
Teva Pharmaceuticals USA, Inc.10$289
SK Life Science, Inc.11$286
Axsome Therapeutics, Inc.11$197
Impel Pharmaceuticals Inc.10$196
Cycle Pharmaceuticals Inc8$184
Sumitomo Pharma America, Inc.8$180
Johnson & Johnson6$155
Alkermes, Inc.1$125
MDD US Operations, LLC1$125
Catalyst Pharmaceuticals, Inc.6$119
Otsuka America Pharmaceutical, Inc.5$103
Merz Pharmaceuticals, LLC3$100
Amneal Pharmaceuticals LLC6$97
Tanabe Pharma America, Inc.4$91
ANI Pharmaceuticals, Inc.3$77
CSL Behring2$69
Biohaven Pharmaceutical Holding Company Ltd.4$67
Aucta Pharmaceuticals, Inc.3$50
Banner Life Sciences, LLC2$41
Kyowa Kirin, Inc.2$35
E.r. Squibb & Sons, L.L.C.2$30
Jazz Pharmaceuticals Inc.1$27
Mallinckrodt Hospital Products Inc.1$26
Vanda Pharmaceuticals Inc.1$26
Otsuka Pharmaceutical Development & Commercialization, Inc.1$24
Averitas Pharma Inc.1$24
Forte Bio-pharma LLC1$22
Vertex1$22
Xeris Pharmaceuticals, Inc.1$20
Scilex Pharmaceuticals Inc.1$19
Boston Scientific1$18
Bioventus LLC1$17
Avanir Pharmaceuticals, Inc.1$17
Neurelis, Inc.1$16
Neuronetics, Inc.1$13

How this compares

$41,755 in reported general payments places this provider in the 75th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$62,178
Medicare patients
274
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →